"Our lead product, PRP, represents an exciting and novel method to control the threat of resistant tumors which if left untreated, can ultimately lead to patient death," said James Nathanielsz, Propanc's Chief Executive Officer. "What is also important, is that PRP targets cancer stem cells, but leaves healthy stem cells alone. This means it is less toxic than standard treatments. We believe PRP could become a welcome addition to the treatment process for many aggressive cancer types, like pancreatic and ovarian cancers, where patient prognosis is often poor, when diagnosed. We therefore think this will be an attractive, novel therapy for those Pharmaceutical, Biotech or Mid-Tier Specialty Companies serious about treating this killer disease."
Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals.
Partner International is a leading corporate development firm with offices in the US, Canada, Australia and Switzerland, whose highly experienced team with all therapeutic areas, including drugs, diagnostics, vaccines and medical devices, has led to both buy- and sell-side transactions in markets around the world. President and CEO, Joanne Ball-Gautschi said "We are very pleased to be representing Propanc. PRP is a very exciting breakthrough in cancer therapeutics and we expect significant response from the industry."
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Logo - http://photos.prnewswire.com/prnh/20160429/361516LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/propanc-engages-two-advisory-firms-to-identify-strategic-partnering-opportunities-300276743.html
SOURCE Propanc Health Group Corporation